Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04695431 · ClinicalTrials.gov registry record
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
A clinical trial, sponsored by Blueprint Medicines Corporation.
- Completed
- Registry status
- 317
- Enrollment target
NCT04695431: Completed study, sponsored by Blueprint Medicines Corporation.
NCT04695431 is a clinical trial that has completed, run by Blueprint Medicines Corporation. The registered enrollment target is 317 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04695431 has completed, sponsored by Blueprint Medicines Corporation.
- COMPLETED
- Registry status
- 317 participants
- Enrollment target
Study Summary
BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.
Primary Outcome
Overall Survival defined as time from initiation of systemic treatment to death from any cause
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2021-10-04 |
What the finished NCT04695431 record still lists
NCT04695431 is an observational study that tracks outcomes without assigning an intervention. The registered 317 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04695431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04695431 about?
NCT04695431 is a clinical study titled "Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM". BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.
What is the current status of trial NCT04695431?
This trial is currently completed. The enrollment target is 317 participants. The study started on 2020-12-02. Estimated completion is 2021-10-04.
Who is sponsoring clinical trial NCT04695431?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04594642 · 317 participants · Phase 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
- NCT04977453 · 317 participants · Phase 1
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- NCT05137054 · 317 participants · Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- NCT05382754 · 317 participants · NA
Home Apnea Testing in CHildren Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI